Dublin-based Mallinckrodt, a global specialty pharmaceutical company, and Luxembourg-based CVC Capital Partners have entered into a definitive agreement under which CVC’s Fund IX will acquire Mallinckrodt’s Therakos business for US$925m….
Dublin-based Mallinckrodt, a global specialty pharmaceutical company, and Luxembourg-based CVC Capital Partners have entered into a definitive agreement under which CVC’s Fund IX will acquire Mallinckrodt’s Therakos business for US$925m….
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference


